AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16741306 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm for SPECT analysis
Number of subjects: 53
Study 16741306 — intervention group
Group type: COMPARATOR
Intervention: Conventional visual assessment
Number of subjects: 53
Study 16741306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined visual and automated approach
Number of subjects: 53
Study 14672645 — intervention group
Group type: EXPERIMENTAL
Intervention: REACT intervention strategies including community organization, public education, professional education, and patient education.
Number of subjects: 20
Study 14672645 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities (control group).
Number of subjects: 20
Study 11606347 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Trendelenburg position
Number of subjects: 739
Study 11606347 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 739
Study 9675626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg/2 mL)
Number of subjects: 50
Study 9675626 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (30 mg/mL)
Number of subjects: 50
Study 8129120 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural sufentanil 50 micrograms
Number of subjects: 30
Study 8129120 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural sufentanil 50 micrograms
Number of subjects: 30
Study 2572618 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole (200 mg)
Number of subjects: 17
Study 1101099 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 50
Study 1101099 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 50
Study 31238414 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Chamber Maintainer (ACM)
Number of subjects: 200
Study 31238414 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacosandwich
Number of subjects: 200
Study 31238414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fishhook
Number of subjects: 200
Study 31238414 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigating Vectis
Number of subjects: 200
Study 31238414 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoexpression
Number of subjects: 200
Study 28185899 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy (20-80 mg/day) for 6 weeks
Number of subjects: 34
Study 28185899 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 34
Study 25305567 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 0
Study 25305567 — intervention group
Group type: EXPERIMENTAL
Intervention: Coad (MenACWY‐TT co-administered with DTaP)
Number of subjects: 0
Study 25305567 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY‐TT
Number of subjects: 0
Study 25305567 — intervention group
Group type: COMPARATOR
Intervention: Control (DTaP at 15-18 months)
Number of subjects: 0
Study 23566694 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic enzyme therapy (twice-daily dose for 5 days starting from the first postoperative day)
Number of subjects: 30
Study 23566694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 21285229 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation with 50 mg elemental iron for 14 weeks
Number of subjects: 135
Study 21285229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 19125084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with GaAlAs, wavelength 830 nm, power 100 mW, dose 4 J/cm, for 5 days
Number of subjects: 21
Study 19125084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham treatment)
Number of subjects: 21
Study 19125084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 21
Study 16633139 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 8‐10 mg per day
Number of subjects: 357
Study 16633139 — intervention group
Group type: COMPARATOR
Intervention: Citalopram 20‐40 mg per day
Number of subjects: 357
Study 15256389 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone
Number of subjects: 3421
Study 15256389 — intervention group
Group type: COMPARATOR
Intervention: fluticasone
Number of subjects: 3421
Study 11399688 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol plus theophylline
Number of subjects: 943
Study 11399688 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 943
Study 9357590 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer system for automatic stenosis detection and quantification
Number of subjects: 49
Study 9357590 — intervention group
Group type: COMPARATOR
Intervention: Individual radiologists
Number of subjects: 49
Study 8106898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 0
Study 8106898 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic and anti-platelet therapy
Number of subjects: 0
Study 3605188 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of NPH and tolazamide
Number of subjects: 12
Study 3605188 — intervention group
Group type: COMPARATOR
Intervention: NPH alone
Number of subjects: 12
Study 30856112 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD)
Number of subjects: 27
Study 30856112 — intervention group
Group type: COMPARATOR
Intervention: National Institute on Aging (NIA) recommended diet
Number of subjects: 27
Study 27988420 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptima HPV Assay (AHPV)
Number of subjects: 3473
Study 27988420 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture® 2 High‐Risk HPV DNA Test® (HC2)
Number of subjects: 3473
Study 27988420 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptima HPV Assay (AHPV) with abnormal LBC and HPV 16/18/45
Number of subjects: 3473
Study 27988420 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture® 2 High‐Risk HPV DNA Test® (HC2) with abnormal cytology or HPV persistence for 12 months
Number of subjects: 3473
Study 27988420 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptima HPV Assay (AHPV) and Hybrid Capture® 2 High‐Risk HPV DNA Test® (HC2)
Number of subjects: 3473
Study 26667262 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept and Bromfenac
Number of subjects: 27
Study 26667262 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept only (Control)
Number of subjects: 27
Study 23361101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedra-free dietary supplements (four types), ingested three times daily for 3 days
Number of subjects: 12
Study 23361101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedra-free dietary supplements (four types)
Number of subjects: 12
Study 23361101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedra-free dietary supplements (two types)
Number of subjects: 12
Study 23361101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedra-free dietary supplements
Number of subjects: 12
Study 21145532 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily, preservative-free ketorolac 0.45%
Number of subjects: 511
Study 21145532 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 511
Study 18445111 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (male: 0.6 g/kg, female: 0.5 g/kg)
Number of subjects: 20
Study 18445111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18445111 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 20
Study 17135158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysmo-off (5 g twice daily for 4 days, one day prior to and three days after menstruation)
Number of subjects: 120
Study 17135158 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (50 mg twice daily for 4 days, one day prior to and three days after menstruation)
Number of subjects: 120
Study 12665490 — intervention group
Group type: EXPERIMENTAL
Intervention: 192Ir with 15 Gy at 2 mm from the source axis
Number of subjects: 120
Study 12665490 — intervention group
Group type: EXPERIMENTAL
Intervention: 192Ir with 18 Gy
Number of subjects: 120
Study 12665490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10742724 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir alone (800 mg q8h)
Number of subjects: 996
Study 10742724 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir plus zidovudine
Number of subjects: 996
Study 10742724 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone (200 mg q8h)
Number of subjects: 996
Study 8650247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 0
Study 8650247 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of other agents along with vitamin D
Number of subjects: 0
Study 1666199 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 21
Study 1666199 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 21
Study 1666199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6352611 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g intramuscular ceftazidime
Number of subjects: 72
Study 6352611 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g intramuscular ceftazidime (twice or thrice daily)
Number of subjects: 72
Study 6352611 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (general outcome)
Number of subjects: 72
Study 31724291 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy
Number of subjects: 72
Study 31724291 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 72
Study 31724291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandala painting
Number of subjects: 72
Study 31724291 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 30204523 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity taper (5.9% increase in intensity)
Number of subjects: 11
Study 30204523 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity taper (8.5% decrease in intensity)
Number of subjects: 11
Study 29442610 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Play‐the‐Winner
Number of subjects: 0
Study 29442610 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth‐and‐Death Urn with Immigration
Number of subjects: 0
Study 29442610 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Play‐the‐Winner
Number of subjects: 0
Study 29442610 — intervention group
Group type: COMPARATOR
Intervention: Equal allocation design
Number of subjects: 0
Study 26988767 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mmol beetroot juice (BR)
Number of subjects: 12
Study 26988767 — intervention group
Group type: COMPARATOR
Intervention: 6 mmol sodium nitrate (NIT)
Number of subjects: 12
Study 26988767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12
Study 26988767 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mmol beetroot juice (BR)
Number of subjects: 12
Study 26988767 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mmol sodium nitrate (NIT)
Number of subjects: 12
Study 26988767 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mmol beetroot juice (BR)
Number of subjects: 12
Study 26988767 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mmol sodium nitrate (NIT)
Number of subjects: 12
Study 24510351 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic flow speed (OS) at levels 0.8, 1.2, and 1.8 m/s with dot density (1, 2, and 3 dots/m²)
Number of subjects: 53
Study 24510351 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking parameters and interlimb coordination during navigation
Number of subjects: 53
Study 24510351 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional kinematic data collection
Number of subjects: 53
Study 22984007 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine arm (hub telestrokologist interpreting CT scans)
Number of subjects: 54
Study 22984007 — intervention group
Group type: COMPARATOR
Intervention: Telephone arm (spoke radiologist interpreting CT scans)
Number of subjects: 54
Study 20100963 — intervention group
Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 51
Study 20100963 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 51
Study 18059577 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g.kg(‐1).d(‐1))
Number of subjects: 18
Study 18059577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18059577 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 18
Study 11158747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (1,200 mg twice a day for 4 days, followed by a washout period, then amprenavir plus rifabutin (300 mg QD) for 10 days)
Number of subjects: 24
Study 11158747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (1,200 mg twice a day for 4 days, followed by a washout period, then amprenavir plus rifampin (600 mg QD) for 4 days)
Number of subjects: 24
Study 11158747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 24
Study 11158747 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin
Number of subjects: 24
Study 11158747 — intervention group
Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 24
Study 11158747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir plus rifabutin
Number of subjects: 24
Study 11158747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir plus rifampin
Number of subjects: 24
Study 9039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg + captopril 6.25 mg
Number of subjects: 16
Study 9039154 — intervention group
Group type: COMPARATOR
Intervention: Captopril 6.25 mg + placebo
Number of subjects: 16
Study 8316771 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine alone
Number of subjects: 80
Study 8316771 — intervention group
Group type: COMPARATOR
Intervention: Dapsone alone
Number of subjects: 80
Study 8316771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Hydroxychloroquine + Dapsone)
Number of subjects: 80
Study 3526218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 15
Study 28923526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols (Sativex®)
Number of subjects: 397
Study 28923526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 28214093 — intervention group
Group type: EXPERIMENTAL
Intervention: Education for Christian church leaders on scientific, religious, and cultural aspects of male circumcision (1-day seminar and bi-weekly meetings during the campaign)
Number of subjects: 145028
Study 28214093 — intervention group
Group type: COMPARATOR
Intervention: Standard outreach activities provided by the Ministry of Health
Number of subjects: 145028
Study 26196084 — intervention group
Group type: COMPARATOR
Intervention: Osmotic dilators alone
Number of subjects: 300
Study 26196084 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms buccal misoprostol 3 hours preoperatively
Number of subjects: 300
Study 26196084 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone during dilator placement
Number of subjects: 300
Study 23781269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (5 days)
Number of subjects: 30
Study 23781269 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 30
Study 19717479 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 232
Study 19717479 — intervention group
Group type: COMPARATOR
Intervention: i.v. benzyl penicillin
Number of subjects: 232
Study 17716735 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation of vitamin C (180 mg), vitamin E (30 mg), zinc (22.5 mg), copper (1 mg), lutein (10 mg), zeaxanthin (1 mg), and astaxanthin (4 mg) daily for 12 months (T-AMD group)
Number of subjects: 27
Study 17716735 — intervention group
Group type: COMPARATOR
Intervention: No dietary supplementation (NT-AMD group)
Number of subjects: 27
Study 17378372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 455
Study 17378372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 455
Study 17378372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 455
Study 17378372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 14725410 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 6 months
Number of subjects: 0
Study 14725410 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 12 months
Number of subjects: 0
Study 14725410 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 18 months
Number of subjects: 0
Study 10950003 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10 percent phenylephrine
Number of subjects: 12
Study 10950003 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 12
Study 8972371 — intervention group
Group type: EXPERIMENTAL
Intervention: One intraoperatively adjusted cross suture
Number of subjects: 75
Study 8972371 — intervention group
Group type: EXPERIMENTAL
Intervention: One unadjusted cross suture
Number of subjects: 75
Study 8972371 — intervention group
Group type: COMPARATOR
Intervention: No suture (sutureless)
Number of subjects: 75
Study 1466529 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical nerve stimulation (ENS)
Number of subjects: 64
Study 1466529 — intervention group
Group type: COMPARATOR
Intervention: Placebo ENS
Number of subjects: 64
Study 29223599 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline tartrate
Number of subjects: 206
Study 29223599 — intervention group
Group type: COMPARATOR
Intervention: bupropion hydrochloride sustained-release
Number of subjects: 206
Study 29223599 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 206
Study 29223599 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline NER (measured by corrugator EMG activity)
Number of subjects: 206
Study 26797266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 90
Study 26797266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 90
Study 24796977 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO7% (7% carbohydrate solution)
Number of subjects: 7
Study 24796977 — intervention group
Group type: EXPERIMENTAL
Intervention: lowCHO1.5% (1.5% carbohydrate solution)
Number of subjects: 7
Study 24796977 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 7
Study 22293726 — intervention group
Group type: EXPERIMENTAL
Intervention: Education combined with individual sleep modification training (one‐on‐one group)
Number of subjects: 0
Study 22293726 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene group education (control group)
Number of subjects: 0
Study 20177856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbohydrate administration (glucose, magnesium, potassium)
Number of subjects: 221
Study 20177856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate administration (specifically composed solution)
Number of subjects: 221
Study 20177856 — intervention group
Group type: COMPARATOR
Intervention: Fasting from midnight (control group)
Number of subjects: 221
Study 19040000 — intervention group
Group type: EXPERIMENTAL
Intervention: Alen + calcium group (n = 74) receiving Alen 10 mg once a day and castrate D 600 0.6 g once a day for 24 weeks
Number of subjects: 140
Study 19040000 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 66) receiving castrate D 600 0.6 g once a day for 24 weeks
Number of subjects: 140
Study 16330203 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN)
Number of subjects: 30
Study 16330203 — intervention group
Group type: COMPARATOR
Intervention: Intravenous replacement fluid therapy (FT)
Number of subjects: 30
Study 14576555 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 120
Study 14576555 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% levobupivacaine
Number of subjects: 120
Study 14576555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mug/ml fentanyl
Number of subjects: 120
Study 14576555 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% levobupivacaine and 1 mug/ml fentanyl
Number of subjects: 120
Study 14576555 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% levobupivacaine without fentanyl
Number of subjects: 120
Study 10742638 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT)
Number of subjects: 40
Study 10742638 — intervention group
Group type: COMPARATOR
Intervention: Individual-based treatment (IBT)
Number of subjects: 40
Study 8629887 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methylparatyrosine
Number of subjects: 19
Study 8629887 — intervention group
Group type: COMPARATOR
Intervention: diphenhydramine
Number of subjects: 19
Study 1602291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg d-1, Group I, n = 4)
Number of subjects: 9
Study 1602291 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (Group II, n = 5)
Number of subjects: 9
Study 6715692 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 12
Study 6715692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31250776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravoxel incoherent motion imaging
Number of subjects: 5
Study 28815684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive psychophysiological (CoPs) intervention for 14 weeks
Number of subjects: 64
Study 28815684 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 64
Study 27169837 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg quercetin‐3‐O‐glucoside
Number of subjects: 15